You are here: Home » International » News » Others
Business Standard

Pfizer forecasts about $15 billion in 2021 sales from Covid-19 vaccine

Pfizer is commanding a higher price for its vaccine than some rivals

Pfizer | Coronavirus Vaccine | AstraZeneca

Riley Griffin | Bloomberg 

Under the terms of its supply deal with the US, it is charging $19.50 for each shot of the two-dose regimen

said it expects about $15 billion in revenue this year from the Covid-19 vaccine it developed with BioNTech SE, a sign of returns to come from the industry’s pandemic response efforts.

The vaccine projection primarily includes doses that are expected to be delivered this year under existing contracts, said Tuesday as it reported fourth-quarter earnings, and it may be adjusted as more contracts are reached.

is commanding a higher price for its vaccine than some rivals. Under the terms of its supply deal with the US, it is charging $19.50 for each shot of the two-dose regimen. Rival AstraZeneca, which hasn’t yet gained authorisation for its two-dose vaccine in the US, has said it plans to charge less than $4 per shot.

Excluding its vaccine sales, Pfizer said it expects 2021 full-year revenue of $44.4 billion to $46.4 billion. Annual earnings per share will be $3.10 to $3.20. Chief Executive Officer Albert Bourla had said earlier this month that earnings would top out at $3.10 a share. The guidance was raised primarily because of its shifting vaccine forecast, according to the company. Pfizer fell as much as 4.3 per cent as of 9:45 am on Tuesday in New York.

The Pfizer-BioNTech vaccine, based on new technology called messenger RNA, was more than 90 per cent effective in preventing Covid-19 symptoms in a late-stage clinical trial. Cleared for emergency use in the US, UK and European Union in December, it brought in $154 million in sales in the fourth quarter.

Pfizer and Germany’s BioNTech initially expected to produce 1.3 billion doses of the vaccine, known BNT162b2, this year. They later boosted their output goal to 2 billion doses after a label change allowed doctors to extract six doses instead of five from each vial, and they secured additional manufacturing capacity. The boon to supply will likely add to the companies’ sales.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 03 2021. 01:52 IST